Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer

Miyake, Makito; Tanaka, Nobumichi; Asakawa, Isao; Tatsumi, Yoshihiro; Nakai, Yasushi; Anai, Satoshi; Torimoto, Kazumasa; Aoki, Katsuya; Yoneda, Tatsuo; Hasegawa, Masatoshi; Konishi, Noboru; Fujimoto, Kiyohide

doi:10.1016/j.radonc.2015.04.026

Cited by 12 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy after radical prostatectomy has been shown to worsen LUTS and QOL 17 . Miyake et al 18 reported the deterioration of storage symptoms, especially frequency, after salvage radiotherapy and Ervandian et al 19 worsened LUTS along with long‐term deterioration of several urodynamic parameters after salvage radiotherapy. These might explain the current results of the insignificant improvement of IPSS soon after AUS implantation and the significantly worsening trend of IPSS in the patients receiving radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal changes in patient‐reported outcomes after artificial urinary sphincter implantation

Yokoyama

Masuda

Ito

et al. 2020

LUTS

View full text Add to dashboard Cite

Objective To evaluate the time course of lower urinary tract symptoms (LUTS) after artificial urinary sphincter (AUS) implantation based on individual longitudinal changes of patient‐reported outcomes. Methods This retrospective study included 66 male patients with severe urinary incontinence who were treated with primary AUS implantation between 2009 and 2019. International Consultation on Incontinence Questionnaire‐Short Form (ICIQ‐SF) and International Prostate Symptom Score (IPSS) questionnaires were used to evaluate continence status and LUTS preoperatively, 1, 3, and 12 months after activation, and then annually. The annual changes in scores were calculated with a linear mixed model. Results Of the 66 patients, 63 (95%) achieved complete or social continence (number of pads used ≤1/d) at 1 month after activation. Mean preoperative ICIQ‐SF, IPSS, and IPSS‐quality of life (QOL) score were 18.9, 14.9, and 5.4, respectively; the corresponding scores at 1 month after activation were 4.5, 9.0, and 1.7 (all P < .001), respectively. During the mean follow‐up period of 36 months, the annual changes in the scores from 1 month after activation were 0.51 (P = .002), −0.30 (P = .184), and 0.19 (P < .001), respectively. As for individual IPSS items, while incomplete emptying, frequency, urgency, and weak stream improved significantly 1 month after activation, no significant changes from 1 month after activation were observed except for longitudinal deterioration of incomplete emptying score (0.08/y, P = .029). Conclusion Continence status and QOL score markedly improved by AUS implantation immediately, but deteriorated over time. Improved LUTS were maintained without a worsening trend, however.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal changes in patient‐reported outcomes after artificial urinary sphincter implantation

Yokoyama

Masuda

Ito

et al. 2020

LUTS

View full text Add to dashboard Cite

show abstract

“…Although SRT may achieve biochemical responses, there is no Level-1 evidence that shows a survival benefit [2,3]. Therefore, it is important to understand the additional treatment burden associated with SRT and its effect on health-related quality of life (HRQoL) [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients

et al. 2016

View full text Add to dashboard Cite

“…The baseline (BL) urinary function was prospectively determined by the IPSS, IPSS-QOL index, OABSS, Sexual Health Inventory for Men (SHIM), and a voiding study before implantation and during the post-implant follow-ups that were conducted at 1, 3, 6, 12, 24, 36, 48, and 60 months after implantation. The voiding symptoms-related IPSS (V-IPSS; the sum of questions 1, 3, 5, and 6) and storage symptoms-related IPSS (S-IPSS; the sum of questions 2, 4, and 7) subscores were calculated separately [ 13 ]. PSA level was monitored 1, 3, 6, 12, 18, 24, 30, 36, 48, and 60 months after implantation.…”

Section: Methodsmentioning

confidence: 99%

“…The IPSS has been predominantly utilized as a tool for defining urinary symptom flares, which are termed IPSS flares [ 4 , 8 – 12 ]. Bothersome symptoms after radiotherapy seem to mainly be characterized by storage urinary characteristics including frequency, urgency, and nocturia [ 13 ]. The overactive bladder symptom score (OABSS) was developed in 2006 as an evaluation tool for patients with overactive bladder syndrome (OAB) and has been validated in Japanese as well as in other populations [ 14 – 16 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the combined use of the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) as an assessment tool for urinary symptom flare after iodine-125 (125I) implant brachytherapy. The association between urinary symptom flare and prostate-specific antigen (PSA) bounce was investigated.MethodsChanges in the IPSS and OABSS were prospectively recorded in 355 patients who underwent seed implantation. The percentage distribution of patients according to the difference between the flare peak and post-implant nadir was plotted to define significant increases in the scores. The clinicopathologic characteristics, treatment parameters, and post-implant dosimetric parameters were compared between the non-flare and flare groups. PSA bounce was defined as an elevation of ≥0.1 ng/mL or ≥0.4 ng/mL compared to the previous lowest value, followed by a decrease to a level at or below the pre-bounce value.ResultsA clinically significant increase required an IPSS increase of at least 12 points and an OABSS increase of at least 6 points based on a time-course analysis of total scores and the QOL index. Assessment only by IPSS failed to detect 40 patients (11%) who had urinary symptom flare according to the OABSS. Univariate and multivariate analyses revealed that patients treated with higher biologically effective doses and those without diabetes mellitus had higher risks of urinary flare. There was no statistical correlation between the incidence and time of urinary symptom flare onset and that of a PSA bounce.ConclusionsTo our knowledge, this is the first report to prove the clinical potential of the OABSS as an assessment tool for urinary symptom flare after seed implantation. Our findings showed that persistent lower urinary tract symptoms after seed implantation were attributed to storage rather than to voiding issues. We believe that assessment with the OABSS combined with the IPSS would aid in decision-making in terms of timing, selection of a treatment intervention, and assessment of the outcome.Electronic supplementary materialThe online version of this article (doi:10.1186/s12894-017-0251-1) contains supplementary material, which is available to authorized users.

show abstract

Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer

Cited by 12 publications

References 28 publications

Longitudinal changes in patient‐reported outcomes after artificial urinary sphincter implantation

Longitudinal changes in patient‐reported outcomes after artificial urinary sphincter implantation

The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

Contact Info

Product

Resources

About